Announcements Trials
Browse Landscape

Phase

Phase 1 3

Status

Completed 2Terminated 1

Sponsor Class

OTHER 3INDUSTRY 3OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Conditions

Neoplasms 2873Carcinoma, Non-Small-Cell Lung 2426Breast Neoplasms 2067Colorectal Neoplasms 1245Neoplasm Metastasis 1231Prostatic Neoplasms 1080Melanoma 974Multiple Myeloma 963Ovarian Neoplasms 904Recurrence 852Leukemia, Myeloid, Acute 810Lung Neoplasms 757Pancreatic Neoplasms 752Lymphoma, Non-Hodgkin 727Lymphoma 660Stomach Neoplasms 623Carcinoma, Hepatocellular 566Carcinoma, Renal Cell 546Squamous Cell Carcinoma of Head and Neck 529Leukemia, Lymphocytic, Chronic, B-Cell 493Lymphoma, Follicular 468Head and Neck Neoplasms 451Glioblastoma 435Advanced Solid Tumors 432Small Cell Lung Carcinoma 411Triple Negative Breast Neoplasms 409Lymphoma, Large B-Cell, Diffuse 398Leukemia 394Uterine Cervical Neoplasms 369Advanced Solid Tumor 351

Interventions

Itraconazole 2roniciclib 1aprutumab ixadotin 1anetumab ravtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Interventional × Medical Oncology × Clear all
NCT02824042 2020-07-31

Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole

Bayer

Phase 1 Completed
63 enrolled

Medical Oncology

NCT02368951 2017-07-12

Phase I, Dose-escalation Trial of BAY1187982 in Subjects With Advanced Solid Tumors Known to Express Fibroblast Growth Factor Receptor 2 (FGFR2)

Bayer

Phase 1 Terminated
20 enrolled

Medical Oncology

NCT02457351 2016-05-23

Roniciclib (BAY 1000394) Drug-Drug Interaction (DDI) Study

Bayer

Phase 1 Completed
14 enrolled

Medical Oncology

Data powered by HemOnc (CC BY 4.0) Colophon âš¡